Windlas Biotech — 360° view

Windlas Biotech, a company in the Pharmaceuticals industry, reported revenue of ₹264 crore and net profit of ₹18 crore for the September 2026 quarter.

Windlas Biotech (NSE: WINDLAS) closed at ₹961.25 on 20 Nov 2026, up 19.5% over the past year. Its market capitalisation is ₹1,984 crore and it trades at 29.8 times earnings.

Share price
₹961.25 (20 Nov 2026)
Market cap
₹1,984 Cr (20 Nov 2026)
P/E
29.76 (20 Nov 2026)
Revenue
₹264 Cr (September 2026 quarter)
Net profit
₹18 Cr (September 2026 quarter)
ROCE
15.9% (FY26)
ROE
12.2% (FY26)
Book value
₹276 (FY26)
Dividend yield
0.66% (last 12 months to 20 Nov 2026)
52-week high / low
₹1,181.90 / ₹697.40 (20 Nov 2026)
1-year return
19.5% (to 20 Nov 2026)
Sector
Healthcare
Industry
Pharmaceuticals
Symbol
NSE: WINDLAS

Windlas Biotech Ltd is a leading domestic pharmaceutical formulations contract development and manufacturing organization (CDMO). The company manufactures both solid and liquid pharmaceutical dosage forms and provides a comprehensive range of CDMO services ranging from product discovery, product development, and commercial manufacturing of generic products, including complex generics.

Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.